Thilo J. Zander
Thilo J. Zander
Head of Lymphoma and Myeloma Service, Lucerne Cancer Center LUKS
Bestätigte E-Mail-Adresse bei luks.ch - Startseite
Titel
Zitiert von
Zitiert von
Jahr
A patient with lung adenocarcinoma and RET fusion treated with vandetanib
O Gautschi, T Zander, FA Keller, K Strobel, A Hirschmann, S Aebi, ...
Journal of Thoracic Oncology 8 (5), e43-e44, 2013
1132013
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
S Hofer, K Elandt, R Greil, AF Hottinger, U Huber, D Lemke, C Marosi, ...
Acta oncologica 50 (5), 630-635, 2011
542011
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and …
M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ...
The Lancet Haematology 7 (6), e456-e468, 2020
462020
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
E Zucca, S Rondeau, A Vanazzi, B Østenstad, UJM Mey, D Rauch, ...
Blood 134 (4), 353-362, 2019
212019
Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary …
E Kimby, G Martinelli, B Ostenstad, UJM Mey, D Rauch, BE Wahlin, F Hitz, ...
Blood, The Journal of the American Society of Hematology 124 (21), 799-799, 2014
212014
Promising activity of nelfinavir-Bortezomib-Dexamethasone in proteasome inhibitor–refractory multiple myeloma
C Driessen, R Müller, U Novak, N Cantoni, D Betticher, N Mach, A Rüfer, ...
Blood 132 (19), 2097-2100, 2018
192018
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
S Gilli, U Novak, BM Taleghani, GM Baerlocher, K Leibundgut, Y Banz, ...
Annals of hematology 96 (3), 421-429, 2017
192017
The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory …
C Driessen, R Müller, U Novak, N Cantoni, D Betticher, N Mach, M Gregor, ...
Blood, The Journal of the American Society of Hematology 128 (22), 487-487, 2016
172016
Response to Pembrolizumab in a patient with relapsing Thymoma
T Zander, S Aebi, AC Rast, A Zander, R Winterhalder, C Brand, J Diebold, ...
Journal of Thoracic Oncology 11 (12), e147-e149, 2016
152016
Endocrinologic side effects of oncologic treatment with anti-CTLA-4-antibodies
S Fischli, S Allelein, T Zander, C Henzen
Deutsche medizinische Wochenschrift (1946) 139 (19), 996-1000, 2014
152014
Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
C Kamber, S Zimmerli, F Suter-Riniker, BU Müller, BM Taleghani, ...
Bone marrow transplantation 50 (4), 573-578, 2015
132015
Rituximab plus lenalidomide versus rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. First analysis of survival endpoints of the randomized …
E Kimby, S Rondeau, A Vanazzi, B Ostenstad, UJM Mey, D Rauch, ...
Blood, The Journal of the American Society of Hematology 128 (22), 1099-1099, 2016
122016
Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer
MW Huellner, TP Hennedige, R Winterhalder, T Zander, SK Venkatesh, ...
Cancer Imaging 12 (1), 212, 2012
122012
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
P Samaras, M Bargetzi, DC Betticher, MA Duchosal, D Heim, U Hess, ...
Swiss medical weekly 145, 2015
112015
The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy
S Toggweiler, Y Odermatt, A Brauchlin, T Zander, A Müller, M Zuber, ...
Clinical cardiology 36 (4), 201-206, 2013
102013
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for …
O Gautschi, SI Rothschild, Q Li, K Matter-Walstra, A Zippelius, ...
Clinical lung cancer 18 (3), 303-309, 2017
92017
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients
I Prediletto, SA Farag, U Bacher, B Jeker, BM Taleghani, R Brégy, ...
Bone marrow transplantation 54 (12), 1923-1925, 2019
82019
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
IG Amsler, B Jeker, B Mansouri Taleghani, U Bacher, D Betticher, T Egger, ...
Leukemia & lymphoma 60 (2), 511-514, 2019
72019
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
U Gössi, B Jeker, B Mansouri Taleghani, U Bacher, U Novak, D Betticher, ...
Hematological oncology 36 (2), 436-444, 2018
62018
INDEPENDENT REVIEW OF CT RESPONSES IN THE TRIAL SAKK35/10 COMPARING RITUXIMAB WITH OR WITHOUT LENALIDOMIDE IN UNTREATED FL PATIENTS IN NEED OF THERAPY: 011
E Zucca, A Vanazzi, B Ostenstad, U Mey, D Rauch, B Wahlin, F Hitz, ...
Hematological Oncology 33, 105-106, 2015
62015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20